CD Capital
VC Fund
Shanghai, China
CD Capital is a venture capital firm specialized in life sciences and medical technology. They are currently managing both RMB and USD funds with total size of $600M. CD Capital is operated by a professional team with diversified and profound industry backgrounds. They have made over 40 investments with high growth potential and earned a reputationas a premier venture capital firm with main focus on China healthcare industry. With broad network around China and the world, they have been able to seize the global trend, capture investment opportunities as well as help to define the future for China healthcare industry. Ultimately, they strive to grow best-in-class companies and deliver solid financial return to their investors.
- Total investments:
- 73
- Last investment:
- Lead investor:
- 37%
Last updated:
For AI agents: llms.txt
Industries CD Capital invests in
Stages CD Capital invests in
Countries CD Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1.4M–$15M
- Series A
- $1.5M–$32M
- Series B
- $7.6M–$34M
Investment Focus
Industry
- Health Care 27 (37%)
- Biotechnology 21 (29%)
- Medical Device 16 (22%)
- Medical 13 (18%)
- Manufacturing 10 (14%)
Stage
- Series A 26 (36%)
- Series B 16 (22%)
- Seed 7 (10%)
- Angel 4 (5%)
- Series C 4 (5%)
Country
- China 45 (62%)
- United States 6 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Chen Ji
Investment Director
|
Investment Director | Total investments: 1 | Find email | |
Ching Tan
Founding Partner, Managing Partner & Chairman
|
Founding Partner, Managing Partner & Chairman | Total investments: 0 | Find email | |
|
Ding Guanhua
Investment Director
|
Investment Director | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| CORE Biomedicine is a private, preclinical-stage biotechnology company that specializes in drug discovery and development for oncology. | $21M / Series A / Jul 28, 2026 | ||
| Genlight develops innovative treatment solutions for epilepsy and other neurological diseases. Genlight is headquartered in Hangzhou, China. | Series C / May 12, 2026 | ||
|
Pipi Bear
|
Pipi Bear is a creator of living robots and health goods, with a focus on those that improve the lives of the elderly. | Series A / Apr 16, 2026 | |
Senas Medical
|
Senas Medical focuses on innovative cardiac electrophysiology solutions. | $14.3M / Series A / Jan 16, 2026 | |
| Develops a healthcare device with a neuromodulation approach to treat heart failure. | $32M / Series A / Sep 25, 2025 | ||
Greenon Biotech
|
Greenon Biotech specializes in the research, development, production, and promotion of alternative antibiotic preparations for animals, which primarily include bacteriophages, probiotics, plant extracts, novel acid preparations, high-efficiency disinfectants, and so on. | $10M / Seed / Jun 17, 2025 | |
|
Greenon Biotech
|
Greenon Biotech specializes in the research, development, production, and promotion of alternative antibiotic preparations for animals, which primarily include bacteriophages, probiotics, plant extracts, novel acid preparations, high-efficiency disinfectants, and so on. | $1.4M / Seed / Jan 13, 2025 | |
Qihe Biotech
|
Qihe Biotech develops novel genome editing technologies with an emphasis on making them autonomous and programmable. | $27.5M / Series A / Dec 02, 2024 | |
Healingovation
|
Healingovation is a med-tech company that specializes in the development and manufacturing of surgical robots, intelligent diagnosis and treatment equipment. | $8.3M / Seed / May 14, 2024 | |
|
Greenon Biotech
|
Greenon Biotech specializes in the research, development, production, and promotion of alternative antibiotic preparations for animals, which primarily include bacteriophages, probiotics, plant extracts, novel acid preparations, high-efficiency disinfectants, and so on. | $14.2M / Seed / Jan 23, 2024 | |
| See all 73 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does CD Capital invest in?
CD Capital invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series A and Series B stage. Most of the 73 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does CD Capital invest in?
CD Capital typically joins rounds of $1.4M–$15M at Seed, $1.5M–$32M at Series A and $7.6M–$34M at Series B. These are whole funding-round sizes, not CD Capital's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds CD Capital took part in.
How do I contact CD Capital?
Public channels for CD Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at CD Capital?
The team at CD Capital includes Chen Ji (Investment Director), Ching Tan (Founding Partner, Managing Partner & Chairman) and Ding Guanhua (Investment Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
